What is HC Wainwright’s Estimate for VolitionRx Q4 Earnings?

VolitionRx Limited (NYSE:VNRX) – Equities research analysts at HC Wainwright lowered their Q4 2025 EPS estimates for shares of VolitionRx in a report released on Monday, August 18th. HC Wainwright analyst Y. Chen now expects that the company will post earnings per share of $0.04 for the quarter, down from their prior forecast of $0.09. The consensus estimate for VolitionRx’s current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for VolitionRx’s Q2 2026 earnings at $0.04 EPS and Q4 2026 earnings at $0.04 EPS.

Several other analysts also recently commented on the stock. Jones Trading upgraded shares of VolitionRx to a “strong-buy” rating and set a $3.00 target price on the stock in a report on Tuesday, June 10th. Wall Street Zen assumed coverage on shares of VolitionRx in a report on Thursday, May 15th. They set a “sell” rating on the stock. Finally, D. Boral Capital restated a “buy” rating and set a $5.00 target price on shares of VolitionRx in a report on Friday, August 15th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $3.50.

VolitionRx Price Performance

Shares of NYSE:VNRX opened at $0.6730 on Tuesday. The company has a market capitalization of $69.98 million, a price-to-earnings ratio of -1.87 and a beta of 1.26. The firm’s 50 day simple moving average is $0.70 and its 200 day simple moving average is $0.59. VolitionRx has a fifty-two week low of $0.3951 and a fifty-two week high of $0.94.

Insider Buying and Selling

In other VolitionRx news, Director Guy Archibald Innes acquired 78,125 shares of the stock in a transaction dated Tuesday, August 5th. The shares were bought at an average cost of $0.64 per share, for a total transaction of $50,000.00. Following the completion of the acquisition, the director directly owned 966,814 shares of the company’s stock, valued at approximately $618,760.96. This trade represents a 8.79% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Cameron John Reynolds acquired 78,125 shares of the stock in a transaction dated Tuesday, August 5th. The stock was acquired at an average price of $0.64 per share, for a total transaction of $50,000.00. Following the completion of the acquisition, the chief executive officer directly owned 2,609,847 shares of the company’s stock, valued at $1,670,302.08. The trade was a 3.09% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought 188,750 shares of company stock worth $118,175 over the last quarter. 10.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On VolitionRx

Hedge funds and other institutional investors have recently made changes to their positions in the company. Blair William & Co. IL bought a new position in shares of VolitionRx in the second quarter valued at $30,000. Two Sigma Securities LLC bought a new position in shares of VolitionRx in the fourth quarter valued at $29,000. Millennium Management LLC bought a new position in VolitionRx during the fourth quarter worth $36,000. Northwestern Mutual Wealth Management Co. bought a new position in VolitionRx during the second quarter worth $52,000. Finally, Northern Trust Corp boosted its position in VolitionRx by 32.0% during the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock worth $71,000 after purchasing an additional 28,579 shares during the period. 8.09% of the stock is owned by institutional investors.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.